Sinil Pharmaceutical Valuation
Is A012790 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A012790 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A012790 (₩6970) is trading below our estimate of fair value (₩10598.48)
Significantly Below Fair Value: A012790 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A012790?
Other financial metrics that can be useful for relative valuation.
What is A012790's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₩79.29b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.6x |
Enterprise Value/EBITDA | 2.9x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does A012790's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 31.5x | ||
A260660 Korea Arlico PharmLtd | 25.4x | n/a | ₩77.9b |
A002800 Sinsin Pharmaceutical | 17.5x | n/a | ₩82.1b |
A001540 Ahn-Gook Pharmaceutical | 66.5x | n/a | ₩85.8b |
A004720 PharmGen Science | 16.6x | n/a | ₩95.0b |
A012790 Sinil Pharmaceutical | 5.8x | n/a | ₩79.3b |
Price-To-Earnings vs Peers: A012790 is good value based on its Price-To-Earnings Ratio (5.8x) compared to the peer average (31.5x).
Price to Earnings Ratio vs Industry
How does A012790's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?
Price-To-Earnings vs Industry: A012790 is good value based on its Price-To-Earnings Ratio (5.8x) compared to the KR Pharmaceuticals industry average (16.5x).
Price to Earnings Ratio vs Fair Ratio
What is A012790's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 5.8x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A012790's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.